Publications by authors named "Christopher Amberger"
Article Synopsis
- A study called ARATA looked at how well a medicine called subcutaneous tocilizumab (TCZ-SC) works for people with rheumatoid arthritis (RA) over two years.
- They found that about 58.7% of patients improved a lot by the end of the study, and many reported feeling better with less pain and fatigue.
- The treatment was safe with few side effects, and patients were happy with how it worked for them!
Objectives: To assess whether tocilizumab treatment is associated with changes in depression symptoms in patients with rheumatoid arthritis (RA) during routine daily care.
Methods: We retrospectively analysed data from a German non-interventional study (ARATA) of adult, tocilizumab-naïve RA patients who initiated subcutaneous tocilizumab and were followed for 52 weeks. The Beck Depression Inventory II (BDI-II) was used to assess symptoms of depression and create baseline subgroups of no (BDI-II<14), mild (14-19), moderate (20-28), and severe (≥29) depression.
The purpose of this study was to assess the impact of enteric-coated mycophenolate sodium (EC-MPS) on skin and pulmonary manifestations of patients with progressive systemic sclerosis (Ssc). A prospective, open-label single-centre trial with EC-MPS 2 × 720 mg/day over 12 months and a long-term follow-up of 50 months were conducted. Modified Rodnan skin score (mRSS) was used to assess the skin and pulmonary function tests to assess the pulmonary involvement.
View Article and Find Full Text PDF